Navigation Links
Pharmasset Initiates Phase 2b Clinical Trial of PSI-7977 for Chronic Hepatitis C Genotypes 1, 2, and 3
Date:8/24/2010

PRINCETON, N.J., Aug 24 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that dosing has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 200mg QD and 400mg QD in combination with pegylated interferon alfa 2a and ribavirin, the current standard of care (SOC) in patients with HCV genotype 1 who have not been treated previously.

"We look for the Phase 2b to further support the efficacy, safety and resistance profile of PSI-7977 over 12 weeks, and to confirm a dose for continued development," stated Michelle Berrey, MD, MPH, Pharmasset's Chief Medical Officer. "Given the potent antiviral activity observed in the Phase 2a study and in vitro evidence for pan-genotype activity, we have also decided to include an exploratory, open label arm of patients with HCV genotype 2 and 3 who will receive a 12 week treatment regimen of PSI-7977 in combination with pegylated interferon and ribavirin. If successful, this shorter treatment regimen would be a first step toward defining a new treatment option for these patients."

About the Phase 2b TrialThe Phase 2b trial is anticipated to enroll approximately 125 patients infected with HCV genotype 1 who have not been treated previously. The primary endpoint of the trial will be the assessment of safety and tolerability of PSI-7977, in combination with SOC over 12 weeks with response-guided therapy allowing discontinuation of SOC at week 24. The trial will be conducted in the U.S. Patients will be randomized (2:2:1) into one of 3 arms:

  • PSI-7977 200mg QD in combination with SOC for 12 weeks, followed by 12 or 36 weeks of SOC;
  • PSI-7977 400mg QD in combination with SOC for 12 weeks, followed by 12 or 36 weeks of SOC;
  • A control arm of matching placebo with SOC for 48 weeks.<
    '/>"/>

  • SOURCE Pharmasset, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
    2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
    3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
    4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
    5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
    6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
    7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
    8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
    9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
    10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
    11. Pharmasset Receives Notice of Allowance
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/1/2014)... , Oct. 1, 2014 Quantum Materials ... volume production of photoactive quantum dots for use ... While offering numerous advantages for solar power generation, ... quantities of quantum dots with which to develop ... them from commercial utilization and acceptance. The company ...
    (Date:10/1/2014)... FREMONT, Calif. , Oct. 1, 2014 ... ARDX ), a clinical-stage biopharmaceutical company focused ... announced positive results from its 371 patient ... patients with constipation-predominant irritable bowel syndrome (IBS-C).  ... and clinically meaningful improvement in IBS-C symptoms ...
    (Date:10/1/2014)... October 1, 2014 Sophia Genetics, ... Sequencing (NGS) data analysis, today launches a unique CFTR ... analysis in a single NGS experiment. The CE-IVD marked ... of variants in a single NGS experiment with clinical ... not been possible to simultaneously analyse all relevant CFTR ...
    Breaking Medicine Technology:Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2
    ... , ... Food and Drug Administration (FDA) has notified health professionals, and ... -- from the use of negative pressure wound therapy (NPWT). ... therapy devices can help in the healing and closure of ...
    ... , ... a leading provider of software solutions to optimize clinical ... release of StudyOptimizer 4, the latest iteration of its ... pharmaceutical companies, DecisionView,s flagship product now includes advanced historical ...
    Cached Medicine Technology:Negative Pressure Wound Devices Draw FDA Notice, Advice 2DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3
    (Date:10/1/2014)... 01, 2014 Innovations announces the upcoming ... broadcast on Monday, October 20, 2014 at 7:30 a.m. ... will go behind the scenes to learn about Break ... will explore the practical help and information Break the ... the warning signs of abuse, how to navigate the ...
    (Date:10/1/2014)... 01, 2014 Anti Aging Clinic (AntiAgingClinic.ca), ... rejuvenating destination of choice, is announcing a discounted cost ... to December. , “We’re doing this because we want ... our top skin clinic in Toronto,” says Dr. Brian ... much at Anti Aging Clinic, including laser facials, genesis ...
    (Date:10/1/2014)... at the occasion of the Leishmaniasis East Africa ... and international leishmaniasis experts, results of a pharmacovigilance ... plan, carried out by MSF, DNDi, and ... were presented to key decision makers in order ... with the combination of Sodium Stibogluconate and Paromomycin ...
    (Date:10/1/2014)... HILLS, CA (PRWEB) October 01, 2014 ... Reshad will speak to a group of dental specialists ... in the northern Spain city of Oviedo. Dr. Reshad ... prosthodontist and lecturer with clients on two continents, will ... complex and aesthetic full mouth reconstruction. , “These specialists ...
    (Date:10/1/2014)... October 01, 2014 Two bicyclists began ... them across the country in an effort to raise ... families. The cyclists, a father-daughter team, plan to ... in Blaine, Washington and finishing in Key West Florida. ... For The Warriors®, a national nonprofit organization that assists ...
    Breaking Medicine News(10 mins):Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 3Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 4Health News:Father-Daughter Cycling Duo to Ride Cross-Country to Benefit Hope For The Warriors 2
    ... , , Gates ... and a Bright One , SEATTLE , Jan. ... & Melinda Gates Foundation, today released his second annual letter -- ... innovation impacts priorities of the foundation. , Gates is optimistic that, ...
    ... or ambidextrous, are more likely to have mental health, ... left-handed children, according to a new study published today ... researchers behind the study, from Imperial College London and ... teachers and health professionals to identify children who are ...
    ... shows it may have prevented, treated eye infections , ... makeup worn thousands of years ago by Queen Nefertiti ... to enhance beauty alone: New research suggests that the ... disease. , Some ancient Egyptians thought their lead-based ...
    ... ... billing and practice management services nationwide, announces today its’ addition of three exceptional leaders ... as Client Managers, while Jamie Hays has come aboard as the Client Accounting Manager. ... Columbus, OH ...
    ... , ... have identified brain networks damaged in Parkinson’s disease have new evidence that these systems ... network appear to respond in a last ditch attempt to rescue the brain. ... Manhasset, NY (Vocus) ...
    ... , SCOTTSDALE, Ariz. , Jan. 22 ... real estate investment trust, announced the execution of a purchase ... office portfolio located in Atlanta, Georgia for approximately ... to a number of conditions. , The medical office portfolio ...
    Cached Medicine News:Health News:Bill Gates Releases Annual Letter 2Health News:Bill Gates Releases Annual Letter 3Health News:Mixed-handed children more likely to have mental health, language and scholastic problems 2Health News:Mixed-handed children more likely to have mental health, language and scholastic problems 3Health News:Explosive Growth Fuels Expansion of ADVOCATE's Management Team 2Health News:Explosive Growth Fuels Expansion of ADVOCATE's Management Team 3Health News:Brain Abnormalities in Parkinson's Patients Develop Before Symptoms Occur, According to Feinstein Scientists 2Health News:Brain Abnormalities in Parkinson's Patients Develop Before Symptoms Occur, According to Feinstein Scientists 3Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia 3
    Portex® Blue Line® cuffed endotracheal tubes come in a wide selection of sizes, each with a standard 15 mm ISO connector., ,Portex® Blue Line® endotracheal tubes are recognized world...
    Portex® Blue Line® cuffed endotracheal tubes come in a wide selection of sizes, each with a standard 15 mm ISO connector., ,Portex® Blue Line® endotracheal tubes are recognized world...
    ... Plus™ Uncuffed Endotracheal Tube w. FlexiSlip™ Stylet, Murphy ... A quality Rusch endotracheal tube with a preloaded ... time and storage space. The stylet has a ... is designed with a soft distal tip to ...
    Cuffed pediatric endotracheal tubes, available from 2.5 mm to 4.5 mm inside diameter. Ruschelit® PVC. Magill tip - nasoral. X-ray opaque line. Graduated. Single use. Sterile...
    Medicine Products: